Synovial hyperplasia

Synovial hyperplasia refers to an increase in the cellularity of the synovial membrane, commonly as a response to chronic inflammation in joint diseases such as rheumatoid arthritis and osteoarthritis[1][7]. It manifests as thickening of the synovial lining—normally only 1–2 cells thick, but often observed as 3 or more layers in disease—and is associated with pannus formation, joint pain, swelling, and eventual destruction of joint cartilage and bone[1][7]. Synovial hyperplasia is a pathological tissue state, not a single molecule or enzyme, and arises from abnormal proliferation and inflammatory activation of synovial fibroblasts, macrophages, and other resident cells[1][7]. While therapies (such as anti-TNF agents and DMARDs) reduce symptoms and inflammation leading to synovial hyperplasia, they do so by targeting specific cytokines and immune processes, not directly by targeting hyperplasia as a molecular entity[4][6]. Synovial hyperplasia is a feature by which disease severity and treatment response can be monitored histologically, but it is not a druggable molecular or receptor target. If seeking a molecular target related to synovial hyperplasia, consider targets such as tumor necrosis factor (TNF), interleukins (IL-1, IL-6, IL-18), or synovial fibroblast markers, as these are druggable and causally related to the process[4][6][2].

Other names

Synovial proliferationSynovial hypertrophySynovial thickeningSynovial membrane hypertrophySynovial lining hyperplasia